(Z)-2-{4-(4-azido-1,2-diphenylbut-1-enyl)phenoxy}ethanol

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (Z)-2-{4-(4-azido-1,2-diphenylbut-1-enyl)phenoxy}ethanol
• 英文别名: 2-[4-[(Z)-4-azido-1,2-diphenylbut-1-enyl]phenoxy]ethanol
• 化学式: C₂₄H₂₃N₃O₂
• 分子量: 385.466
• InChiKey: XDFRJOYSEGRKGS-VHXPQNKSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (Z)-2-{4-(4-azido-1,2-diphenylbut-1-enyl)phenoxy}ethanol 在 potassium carbonate 、 氯化铵 、 锌 作用下， 以 乙醇 、 氯仿 、 水 为溶剂， 反应 10.0h， 生成 phenyl (Z)-4-{4-(2-hydroxyethoxy) phenyl}-3,4-diphenylbut-3-enylcarbamate
  参考文献：
  名称：

  [EN] NOVEL TRIARYLETHYLENE COMPOUNDS AND METHODS USING SAME
  [FR] NOUVEAUX COMPOSÉS DE TRIARYLÉTHYLÈNE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本发明包括用于预防或治疗需要的受试者的癌症的化合物。本发明还包括通过向受试者施用本发明化合物的治疗有效量来预防或治疗受试者的癌症的方法。

  公开号：

  WO2016022325A1
• 作为产物：
  描述：

  欧司哌米 在 sodium azide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 (Z)-2-{4-(4-azido-1,2-diphenylbut-1-enyl)phenoxy}ethanol
  参考文献：
  名称：

  Triarylethylene-indolin-2,3-dione molecular conjugates: design, synthesis, docking studies and anti-proliferation evaluation

  摘要：

  一系列1-三唑基-连结的ospemifene-isatin和O-甲基化ospemifene-isatin共轭物被合成，并对其抗增殖活性进行了测试，针对雌激素反应性细胞和非雌激素反应性细胞。

  DOI：

  10.1039/c9ra08776a

文献信息

• [EN] NOVEL TRIARYLETHYLENE COMPOUNDS AND METHODS USING SAME<br/>[FR] NOUVEAUX COMPOSÉS DE TRIARYLÉTHYLÈNE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：PENN STATE RES FOUND

  公开号：WO2016022325A1

  公开（公告）日：2016-02-11

  The present invention includes compounds useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.

  本发明包括用于预防或治疗需要的受试者的癌症的化合物。本发明还包括通过向受试者施用本发明化合物的治疗有效量来预防或治疗受试者的癌症的方法。
• Novel Triarylethylene Compounds and Methods Using Same
  申请人：The Penn State Research Foundation

  公开号：US20170217914A1

  公开（公告）日：2017-08-03

  The present invention includes compounds useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.
• Triarylethylene-indolin-2,3-dione molecular conjugates: design, synthesis, docking studies and anti-proliferation evaluation
  作者：Sumit Kumar、Gabriella Palma、Shanen Perumal、Mandeep Kaur、Ashona Singh-Pillay、Raghu Raj、Parvesh Singh、Vipan Kumar

  DOI：10.1039/c9ra08776a

  日期：——

  A series of 1H-1,2,3-triazole-linked ospemifene–isatin and O-methylated ospemifene–isatin conjugates were synthesized and assayed for their anti-proliferative activities against estrogen-responsive as well as estrogen-non-responsive cells.

  一系列1-三唑基-连结的ospemifene-isatin和O-甲基化ospemifene-isatin共轭物被合成，并对其抗增殖活性进行了测试，针对雌激素反应性细胞和非雌激素反应性细胞。
• Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents
  作者：Gurleen Kaur、Mohinder P. Mahajan、Manoj K. Pandey、Parvesh Singh、Srinivasa R. Ramisetti、Arun K. Sharma

  DOI：10.1016/j.ejmech.2014.08.050

  日期：2014.10

  The synthesis of some novel Ospemifene derived analogs and their evaluation as anti-breast cancer agents against MCF-7 (ER-positive) and MDA-MB-231 (ER-negative) human breast cancer cell lines are described. Few of these analogs for instance, compounds 6, 7 and 8 are shown to be more effective than recent Selective Estrogen Receptor Modulators (SERMs) i.e. Ospemifene and Tamoxifen, against these cell lines. Compound 8 was relatively more cytotoxic to MCF-7 cells similar to Ospemifene and Tamoxifen, while most potent compounds 6 and 7 were equally effective in inhibiting growth of both ER-positive and ER-negative cell lines. The observed activity profiles were further supported by the docking studies performed against estrogen receptors (ER alpha and ER beta). Compounds 6, 7 and 8 exhibited stronger binding affinities with both ER alpha and ER beta compared to Ospemifene and Tamoxifen. (c) 2014 Elsevier Masson SAS. All rights reserved.